The Journal of Liquid Biopsy
Overview
The Journal of Liquid Biopsy is a scientific journal, published since 2023. The journal's country of origin is United States.
Details
Details
Abbr.
J Liq Biopsy
Start
2023
End
Continuing
Frequency
Quarterly
e-ISSN
2950-1954
Country
United States
Recent Articles
1.
De Luca C, Russo G, Nacchio M, Ingenito M, Palumbo L, Gragnano G, et al.
J Liq Biopsy
. 2025 Mar;
2:100128.
PMID: 40028489
Background: Lung cancer is the leading cause of cancer death worldwide. Over the last decade, molecular testing of a growing number of predictive biomarkers has become mandatory in the management...
2.
Dhar R, Devi A
J Liq Biopsy
. 2025 Mar;
2:100129.
PMID: 40028488
Cancer is an unsolved health crisis worldwide. Extracellular vesicles (EVs) address this problem in a new way. In cancer, early detection is highly challenging, exosomes (a subpopulation of EVs, originating...
3.
Zala U, Patel R, Panchal V, Chaudhari J, Shah V, Shah A
J Liq Biopsy
. 2025 Mar;
2:100127.
PMID: 40028487
Background: One of the main techniques for diagnosing lung cancer is still tissue biopsy. The more recent liquid biopsy technique includes the assessment of fragments of cfDNA, ctDNA, and CTCs,...
4.
Denninghoff V, Garrido-Navas M, Molina-Vallejo M, Garcia-Diaz A, Perez-Villares J, Colmenero-Ruiz M, et al.
J Liq Biopsy
. 2025 Mar;
2:100005.
PMID: 40028486
Liquid biopsy (LB) is a minimally invasive procedure that detects biomarkers in body fluids for real-time monitoring of patients. This study developed a new LB approach to analyze Circulating Epithelial...
5.
Nicolo E, Serafini M, Munoz-Arcos L, Pontolillo L, Molteni E, Bayou N, et al.
J Liq Biopsy
. 2025 Mar;
2:100117.
PMID: 40028485
The human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can capture its spatial and...
6.
Geddam A, Lutfi A, Afghan M, Currie B, Rosenblatt R, Ramirez A, et al.
J Liq Biopsy
. 2025 Mar;
2:100009.
PMID: 40028484
Hepatocellular Carcinoma (HCC) is the most common primary liver carcinoma, accounting for 75-85% of all cases. For patients with advanced unresectable and/or metastatic HCC, treatment options primarily include immunotherapy combinations...
7.
Garcia-Pardo M, Leighl N
J Liq Biopsy
. 2025 Mar;
2:100123.
PMID: 40028483
Molecular genotyping is essential for management of patients newly diagnosed with advanced non-small cell lung cancer (NSCLC). Plasma circulating tumor DNA (ctDNA) testing has emerged as a complement to tumor...
8.
Bamodu O, Chung C, Pisanic 2nd T
J Liq Biopsy
. 2025 Mar;
2:100126.
PMID: 40028482
Liquid biopsies have emerged as groundbreaking tools for minimally invasive monitoring of cancer, encompassing the analysis of Cell-Free DNA (cfDNA), circulating tumor DNA (ctDNA) and exosomes. This paradigm shift offers...
9.
Mirgh D, Krishnan A, Gorai S
J Liq Biopsy
. 2025 Mar;
2:100122.
PMID: 40028481
No abstract available.
10.
Baruah S, Rajak J, Mitra A, Dhara B
J Liq Biopsy
. 2025 Mar;
5:100157.
PMID: 40027946
While the traditional method is a biopsy of the potential tumor tissue, more non-invasive methods have been developed such as the liquid biopsy. It is an emerging, powerful cancer detection...